Broader screening for hepatitis C would be cost effective, study suggests

Broader screening to identify people infected with hepatitis C virus (HCV) would likely be cost effective, according to a new report published in Clinical Infectious Diseases and available online. Significantly reducing HCV-related mortality and morbidity, however, will require a coordinated effort that emphasizes not only increased testing but also linking those infected with the treatment they need.

The HCV epidemic peaked many years ago, but roughly 4 million U.S. residents still suffer the consequences of . A growing proportion of those infected now has advanced disease, including cirrhosis of the liver and liver cancer. Deaths from chronic infection have doubled over the last decade and are expected to more than double again by 2030.

The current "risk factor-based approach to screening has failed to identify at least half of those infected, leading to a situation in which a quarter of those newly diagnosed already suffer from cirrhosis of the liver," said Dr. Phillip O. Coffin, who led a team of researchers, including Drs. John D. Scott, Matthew R. Golden, and Sean D. Sullivan, at the University of Washington in Seattle who estimated the cost-effectiveness and impact of HCV screening.

Adding a one-time screening for all adults between the ages of 20 and 69 and factoring in the costs of managing late-stage versus the costs of attempting to cure patients of hepatitis C, Dr. Coffin's team used statistical modeling techniques to analyze the benefit of broadening screening guidelines. They found that screening all adults was cost effective across a wide range of assumptions related to the costs and effects of screening and treatment. At the same time, the proportion of deaths averted by screening is likely to be relatively small, unless testing efforts are accompanied by substantial increases in successful referral of infected persons for treatment.

"The stealth epidemic of hepatitis C has finally matured, leaving a narrow window of opportunity to find those with advancing disease, connect them with care, and prevent the tragic and costly consequences of and end-stage liver disease," Dr. Coffin said. Doctors are hampered by current overly narrow , and managing chronic HCV infection becomes increasingly expensive as it progresses.

"We need to screen the population, but that won't be enough to make a big difference," Dr. Coffin said. "Hepatitis C is a lot like HIV. The U.S. took a long time to come to the conclusion that we needed to really emphasize testing and efforts to link people to care. is the same. We need a large scale, coordinated effort to identify people with this infection and make sure they get the care they need."

add to favorites email to friend print save as pdf

Related Stories

The economic cost of advanced liver disease

Nov 07, 2011

Health care costs for hepatitis C patients with end-stage liver disease are nearly 2.5 times higher than those in the early stages, according to a Henry Ford Hospital study.

Recommended for you

Ebola isolation at US base 'pretty much vacation'

3 hours ago

With plenty of flat screen TVs, game nights and even an outdoor fire pit, life in isolation for members of the U.S. military who have returned from the Ebola mission in West Africa can look a lot like summer camp.

Chinese-built Ebola center dedicated in Liberia

7 hours ago

China, one of the first countries to send aid to battle Ebola in West Africa, ramped up the assistance significantly Tuesday by opening a 100-bed treatment center in Liberia as rows of uniformed Chinese army ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.